Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Chemotherapy

Maximum tolerated dose determined for bortezomib and carboplatin

Researchers in the United States conducted a study "to determine the maximum-tolerated dose, pharmacodynamics, and safety of the combination of bortezomib and carboplatin in recurrent ovarian cancer. Fifteen patients were treated with a fixed dose of carboplatin (area under the curve [AUC] 5) and increasing doses of bortezomib (.75, 1, 1.3, and 1.5 mg/m²/dose). Patients had to have received upfront chemotherapy and up to two prior chemotherapy regimens for recurrent disease."

"Neurologic evaluation was performed at baseline and...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications